Christina Lang

Spenden & Helfen

Curriculum vitae

Name Christina Lang
Place of birth Landsberg am Lech
Date of birth 28th October 1983
since 09/2010 Graduate programme “Neurodegenerative Disease Research“ (SFB 596), LMU Munich, PhD studies in the group of Prof. Dr. Christian Haass and Dr. Anja Capell, Adolf-Butenandt Institute and DZNE, Munich
 10/2009 - 05/2010 Master thesis in the group of PD Birgit Luber, Institute of Molecular Pathology, Technische Universität München
 02/2009 - 07/2009 Semester abroad at the Victoria University of Wellington, New Zealand; DAAD scholarship and TUM scholarship
 10/2007 - 05/2010 Studies of Molecular Biotechnology, Technische Universität München; Degree: Master of Science (grade: 1.2)
 08/2008 - 02/2009 Voluntary Placement at Roche Diagnostics GmbH, Penzberg
 10/2004 - 09/2007 Studies of Molecular Biotechnology, Technische Universität München; Degree: Bachelor of Science (grade: 1.5)

Project description

Frontotemporal dementia associated risk factors

Frontotemporal lobar degeneration (FTLD) is the second most common cause of dementia in people under the age of 65 years.
FTLD-TDP, the largest subgroup of FTLD, is characterized by ubiquitin-immunoreactive neuronal cytoplasmic or nuclear inclusions containing TAR DNA-binding protein-43 (TDP-43) as their main component. In 2006, mutations in the progranulin (GRN) gene were found to be causative for autosomal dominant FTLD-TDP. Progranulin, an ubiquitously expressed, secreted precursor protein is involved in embryonic development, wound repair, tumour growth and inflammation and discussed as a neurotrophic factor. Interestingly, all known GRN mutations are loss-of-function mutations leading to haploinsufficiency. Therefore, a possible therapeutic approach would be to increase GRN expression in FTLD patients carrying GRN mutations.
Very recently, 7p21, encoding the uncharacterized transmembrane protein TMEM106B, was detected to be a common genetic susceptibility locus for FTLD-TDP. A potential disease mechanism was suggested in which risk-associated polymorphisms at 7p21 increase TMEM106B expression which in turn increases the risk for FTLD-TDP. Furthermore, TMEM106B seems to be an important risk factor even in GRN mutation carriers implying that GRN mutations operate upstream of TMEM106B in a pathogenic cascade. However, the exact mechanism which leads to FTLD-TDP and the relationship between GRN and TMEM106B are still unknown.
In my PhD thesis, I will investigate if TMEM106B has any influence on GRN expression and therefore might it be responsible for a varying age of onset in patients with exactly the same GRN mutation. Furthermore, I will evaluate if there are any drugs which increase GRN levels in order to rescue the haploinsufficiency phenotype in FTLD-TDP patients carrying a GRN mutation.


Our website uses cookies to improve the usability and performance of our services and to track visits. Details about used cookies and ways to opt out can be found in our privacy statement.